Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
Top Page
Entrada Therapeutics Inc
(NASDAQ:TRDA)
Select Model
Select Model
Rating:55Neutral
Price Target:
$14.00
▼(-2.23% Downside)
Action:ReiteratedDate:03/07/26
The score is held back primarily by weak and volatile financial performance, particularly the sharp 2025 reversal into large losses and heavy cash burn. Offsetting this, technicals indicate an improving trend with supportive momentum, and corporate updates provide positive pipeline and regulatory progress plus a stated runway into Q3 2027. Valuation remains only middling because a negative P/E reflects ongoing losses and there is no dividend support.
Positive Factors
Pipeline breadth & regulatory progress
Entrada has diversified RNA programs across neuromuscular and ocular indications plus FDA Rare Pediatric Disease designation. Multiple clinical starts and regulatory recognitions create distinct, durable value pathways and reduce single-program binary risk over the next 2–6 months.
Negative Factors
High cash burn and negative cash flow
Operating and free cash flow turned deeply negative in 2025, indicating the company is consuming significant cash to advance trials. Persistent burn raises durable funding risk, making continued execution dependent on external financing or milestone receipts over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline breadth & regulatory progress
Entrada has diversified RNA programs across neuromuscular and ocular indications plus FDA Rare Pediatric Disease designation. Multiple clinical starts and regulatory recognitions create distinct, durable value pathways and reduce single-program binary risk over the next 2–6 months.
Read all positive factors
Entrada Therapeutics Inc (TRDA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$548.23M
Dividend YieldN/A
Average Volume (3M)218.99K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue Growth-71.42%
EPS Growth-248.91%
CountryUS
Employees183
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.94
Shares Outstanding38,284,313
10 Day Avg. Volume169,940
30 Day Avg. Volume218,985
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)16.73
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue19.61
Enterprise Value/Gross Profit-36.05
Enterprise Value/Ebitda-3.31
Forecast
1Y Price Target
$20.50Price Target Upside43.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.91
Revenue Forecast (FY)$24.92M
Entrada Therapeutics Inc Business Overview & Revenue Model
Company Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody...
How the Company Makes Money
Entrada Therapeutics primarily generates revenue from collaboration and licensing arrangements rather than from selling approved products. Under such agreements, the company may earn (i) upfront payments at contract inception, (ii) research fundin...
Entrada Therapeutics Inc Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 25.42M | 210.78M | 129.01M | 0.00 | 0.00 |
| Gross Profit | 21.32M | 210.78M | 129.01M | 0.00 | 0.00 |
| EBITDA | -142.40M | 47.01M | -321.00K | -95.35M | -50.01M |
| Net Income | -143.75M | 65.63M | -6.68M | -94.62M | -51.16M |
Balance Sheet | |||||
| Total Assets | 377.38M | 526.32M | 469.19M | 252.06M | 305.83M |
| Cash, Cash Equivalents and Short-Term Investments | 295.70M | 420.00M | 351.97M | 188.71M | 291.06M |
| Total Debt | 50.93M | 59.21M | 68.23M | 25.94M | 0.00 |
| Total Liabilities | 71.25M | 97.64M | 226.83M | 39.50M | 7.12M |
| Stockholders Equity | 306.13M | 428.68M | 242.36M | 212.55M | 298.72M |
Cash Flow | |||||
| Free Cash Flow | -129.55M | -44.72M | 134.19M | -96.67M | -55.44M |
| Operating Cash Flow | -128.51M | -41.56M | 139.80M | -93.79M | -50.86M |
| Investing Cash Flow | 116.81M | -27.80M | -138.40M | -148.65M | -4.58M |
| Financing Cash Flow | 887.00K | 102.96M | 21.04M | 479.00K | 307.46M |
Entrada Therapeutics Inc Technical Analysis
Positive
14.32
Price Trends
11.94
Positive
11.12
Positive
8.62
Positive
Market Momentum
0.50
Negative
66.74
Neutral
96.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Positive. The current price of 14.32 is above the 20-day moving average (MA) of 12.60, above the 50-day MA of 11.94, and above the 200-day MA of 8.62, indicating a bullish trend. The MACD of 0.50 indicates Negative momentum. The RSI at 66.74 is Neutral, neither overbought nor oversold. The STOCH value of 96.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRDA.
Entrada Therapeutics Inc Risk Analysis
Entrada Therapeutics Inc disclosed 93 risk factors in its most recent earnings report. Entrada Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Entrada Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $548.23M | -2.96 | -39.83% | ― | -71.42% | -248.91% | |
54 Neutral | $282.98M | -1.51 | -53.83% | ― | -10.57% | 1.98% | |
52 Neutral | $143.22M | 6.18 | 17.46% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $178.98M | -3.75 | -40.85% | ― | ― | -38.23% |
* Healthcare Sector Average
TRDA
Entrada Therapeutics Inc
14.32
6.47
82.42%
BDTX
Black Diamond Therapeutics
2.50
1.08
76.06%
CCCC
C4 Therapeutics
2.90
1.69
139.67%
SGMT
Sagimet Biosciences, Inc. Class A
5.59
3.36
150.67%
Entrada Therapeutics Inc Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Entrada Therapeutics highlights RNA pipeline progress and outlook
Positive
Jan 8, 2026
On January 8, 2026, Entrada Therapeutics reported significant 2025–early 2026 progress across its RNA-based pipeline for neuromuscular and ocular diseases, including completion of Cohort 1 dosing in the global Phase 1/2 MAD ELEVATE-44-201 st...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.